COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07EUO
|
|||
Drug Name |
Naltrexone
|
|||
Synonyms |
naltrexone; 16590-41-3; ReVia; Vivitrol; N-Cyclopropylmethylnoroxymorphone; Vivitrex; Celupan; Naltrexone hydrochloride; Naltrexonum [INN-Latin]; Naltrexona [INN-Spanish]; UNII-5S6W795CQM; N-Cyclopropylmethyl-14-hydroxydihydromorphinone; Naltrexone [USAN:INN:BAN]; CCRIS 3506; HSDB 6750; EINECS 240-649-9; UM-792; BRN 3596648; 5S6W795CQM; CHEBI:7465; (-)-Naltrexone; Nemexin; EN-1639A [AS HYDROCHLORIDE]; Naltrexone
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1] | |
Other Indication | Chronic alcoholism | Approved | [2] | |
Therapeutic Class |
Antiviral Agents
|
|||
Structure |
Download2D MOL |
|||
Formula |
C20H23NO4
|
|||
Canonical SMILES |
C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O
|
|||
InChI |
1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1
|
|||
InChIKey |
DQCKKXVULJGBQN-XFWGSAIBSA-N
|
|||
CAS Number |
CAS 16590-41-3
|
|||
PubChem Compound ID | ||||
ChEBI ID |
CHEBI:7465
|
References | Top | |||
---|---|---|---|---|
1 | ClinicalTrials.gov (NCT04365985) Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19. U.S. National Institutes of Health. | |||
2 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 074918. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.